STUELPNAGEL JOHN R

About STUELPNAGEL JOHN R

John R. Stuelpnagel, D.V.M., is best known for his long-standing role as Chairman of the Board at 10x Genomics, a position he has held since 2013. His career is closely tied to the growth of some of the most influential names in genomics and life sciences. He is widely recognized as a seasoned entrepreneur and executive who helped build and scale companies commercializing disruptive technologies. At Illumina, which he co-founded, he served as the company’s first Chief Executive Officer and later remained with the business for 12 years, contributing to its evolution from a private startup into a global leader in next-generation sequencing. After leaving Illumina in 2009, he co-founded Ariosa Diagnostics, where he served as Executive Chairman until the company’s acquisition by Roche in 2015. He also chaired Sequenta before its merger with Adaptive Biotechnologies. In addition, he has served as Chairman of Element Biosciences and has remained active in the life sciences ecosystem through board service at companies such as Fabric Genomics, Inscripta, and Encoded Therapeutics. His background reflects deep expertise in corporate strategy, commercialization, scaling high-growth businesses, and guiding technology-driven organizations through important strategic milestones. Earlier in his career, he worked at CW Group. He holds a Doctor of Veterinary Medicine degree, a bachelor’s degree in biochemistry from the University of California, Davis, and an MBA from UCLA. From a governance perspective, his profile is associated with strategic oversight of innovative biotechnology companies, including support for operational growth, financing, and M&A transactions.